Recombinant Human Apo-SAA1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Description | Serum amyloid A proteins (SAA) represents a family of apolipoproteins that circulates in association with high-density lipoproteins (HDL). The level of apo-SAA, normally 1-5 μg/ml in plasma, increases 500-1000 fold within 24 hours of an inflammatory stimulus and, under these conditions, is the most abundant HDL apo-lipoprotein. The human SAA gene codes for a 122 amino acid nonglycosylated polypeptide, which contains an 18 amino acid N-terminal sequence. Recombinant human apo-SAA1 is an 11.7 kDa protein containing 105 amino acid residues. |
---|---|
BiologicalActivity | Determined by its ability to chemoattract human monocytes using a concentration range of 10.0-100.0 ng/ml. |
Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
Endotoxin | Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg). |
Protein Content | Verified by UV Spectroscopy and/or SDS-PAGE gel. |
Storage | -20°C |
Precautions | Recombinant Human Apo-SAA1 is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.